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Abstract 
Background: Paraneoplastic neurologic syndromes (PNS) pose quite an uncommon 
neurological complication, affecting less than 1% of patients with breast cancer. Nearly one 
third of these patients lack detectable onconeural antibodies (ONAs), and improvement in 
neurologic deficits with concomitant cancer treatments is achieved in less than 30% of cases.  
Case Presentation: A 42-year-old, premenopausal woman presented with facial paralysis on 
the central left side accompanied by a left tongue deviation, an upward vertical nystagmus, 
moderate spastic paraparesis, dystonic posturing of the left foot, lower limb hyperreflexia 
and bilateral extensor plantar reflex. After ruling out all other potential neurologic causes, 
PNS was suspected but no ONAs were found. A PET-CT scan 
 detected increased metabolism in the right breast, as well as an ipsilateral thoracic 
interpectoral adenopathy. Core biopsy confirmed the presence of an infiltrating duct 
carcinoma. After breast surgery, the neurologic symptoms disappeared. One week later, the 
patient was readmitted to the hospital with a bilateral fatigable eyelid ptosis, and two weeks 
later, there was a noticeable improvement in eyelid ptosis, accompanied by a rapid and 
progressive development of lower spastic paraparesis. She started adjuvant treatment with 
chemotherapy with marked clinical and neurological improvement, and by the end of 
radiotherapy, there were no signs of neurologic impairment.  
Conclusion: This case study highlights the importance of a high level of vigilance for the 
detection of PNS, even when ONAs are not detected, as the rapid identification and 
treatment of the underlying tumor offers the best chance for a full recovery. 
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Background 
Paraneoplastic neurologic syndromes (PNS) pose quite an uncommon neurological 
complication in breast cancer, affecting less than 1% of patients [1, 2]. The etiology of 
PNS remains unknown and is believed to be of an autoimmune origin, resulting from 
the immune cross-reactivity that occurs between tumor cells and components of the 
nervous system [3, 4]. In response to the developing cancer, a patient’s immune system 
produces tumor-directed antibodies known as onconeural antibodies (ONAs). 
Importantly, there is substantial evidence to suggest that nearly one third of these 
patients lack detectable ONAs, and improvement in neurologic deficits with 
concomitant cancer treatments is thus achieved in less than 30% of patients [5]. 
Case Presentation 
A 42-year-old, Caucasian, premenopausal woman was admitted to the emergency room, for acute 
left facial palsy. Fifteen days earlier, she had noticed weakness in her left leg with hypoesthesia but 
without any changes in sphincter function. A neurological examination revealed facial paralysis on the 
central left side accompanied by a left tongue deviation, an upward vertical nystagmus, moderate 
spastic paraparesis, dystonic posturing of the left foot, lower limb hyperreflexia and bilateral extensor 
plantar reflex. Myoclonus and saccades were both absent. There were no other discernible 
neurological abnormalities, such as with sensorial perception, sphincter control and cerebellar 
function. The patient did not experience any disturbances associated with memory, confusion or 
visual changes. T2-weighted brain magnetic resonance imaging (MRI) revealed small nonspecific 
white matter lesions (in the periventricular white matter, right corona radiata and bilateral frontal 
subcortical) without enhancement. The brain computed tomography (CT) was normal. In addition, 
there were no observable lesions in the spine MRI. Likewise, somatosensory nerve action potentials 
and cerebrospinal fluid (CSF) analyses were normal. Thus, after ruling out all other potential 
neurologic causes, PNS was suspected. A full workup, including a complete history and physical exam, 
chest X-ray, diagnostic bilateral mammogram with ultrasound, chest, abdominal and pelvic CT and a 
panel of blood tests, which included serum ONAs (anti-Hu, anti-Ri, anti-Yo, anti-Ma and anti-
amphiphysin) and tumor markers, were performed. No ONAs were found and the investigation did 
not uncover any primary neoplasm. For this reason, a whole-body positron emission tomography-
computed tomography (FDG-PET/CT) (fig. 1, fig. 2) scan was performed. The FDG-PET/CT detected 
increased metabolism in both breasts, with greater intensity in the right, as well as an ipsilateral 
thoracic interpectoral adenopathy. The right breast MRI (fig. 3) revealed a suspicious retroareolar 
nodule with axillary lymph node involvement. A core biopsy confirmed the presence of an infiltrating 
duct carcinoma. The patient underwent a right breast lumpectomy with axillary lymph node 
dissection, which revealed metastases in four lymph nodes (N). The histology results revealed a 1.5-
cm high-grade focus, with an invasive ductal carcinoma, pT1c, pN2 (4N+/13N), positive ER and PR, 
positive HER-2 (3+, SISH confirmation) and a Ki67 greater than 30%. Following breast-conserving 
surgery, the neurologic symptoms disappeared. One week later, the patient was readmitted to the 
hospital with a bilateral fatigable eyelid ptosis. CSF analyses and image scans (brain and spine MRI) 
did not reveal any abnormalities. In addition, the repetitive nerve stimulation and single-fiber EMG 
results were normal and the anti-acetylcholine receptor antibodies were negative. Intravenous 
immunoglobulin therapy was performed, but it did not yield any results. Two weeks after admission, 
there was a noticeable but slight improvement in eyelid ptosis, which was accompanied by a rapid 
and progressive development of lower spastic paraparesis. Four weeks after surgery, the patient 
started adjuvant chemotherapy, consisting of four cycles of the AC protocol (cyclophosphamide and  
doxorubicin), followed by 4 cycles of docetaxel, once every 3 weeks, in association with trastuzumab, 
every 3 weeks for a total of 18 cycles. At the end of chemotherapy, the patient showed marked clinical 
and neurological improvement. After chemotherapy, the patient began tamoxifen, and sequential 
radiotherapy was performed. By the end of the radiotherapy, there were no signs of neurologic 
impairment. The patient was reviewed by our Oncology Department, once the trastuzumab protocol 
was completed. The T2-weighted brain MRI was repeated and revealed the same nonspecific white 
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matter lesions observed previously. The patient was in complete clinical remission without symptoms 
and any neurological disturbances and was leading a normal life. 
Discussion 
According to the Paraneoplastic Neurological Syndrome Euronetwork diagnostic 
criteria [6], our patient fulfilled the requirements for the clinical diagnosis of possible 
non-classical PNS. The first time our patient was admitted to the hospital, she 
presented with neurologic symptoms that were characterized by facial paralysis of the 
central left side, left tongue deviation with an upward vertical nystagmus, moderate 
spastic paraparesis, dystonic posturing of the left foot, lower limb hyperreflexia and 
bilateral extensor plantar reflex. All of these symptoms may include more than one 
level of motor involvement, with both the spinal cord and brainstem being engaged. 
Facial paralysis, tongue deviation and vertical nystagmus are consistent with brainstem 
encephalitis, which is present in one third of patients with paraneoplastic 
encephalomyelitis (PEM); the clinical presentation of PEM reflects the distribution of 
this multifocal inflammatory condition that is associated with remote neoplasia. 
Neuroimaging studies of PEM using MRI may show increased signal intensity on the T2-
weighted scan, which is consistent with the inflammatory process. However, certain 
neuroimaging studies are standard, as reported in the present case study [7]. Given that 
the CSF examination was normal, the proposed diagnosis was less likely, as CSF may 
show elevated white cell counts, oligoclonal bands, and intrathecal synthesis of IgG, 
indicating an immune-mediated or inflammatory etiology [3]. 
A second neurological examination following surgery revealed a bilateral fatigable 
eyelid ptosis, suggesting a neuromuscular postsynaptic disorder such as myasthenia 
gravis (MG). The link of MG with tumors other than thymoma remains controversial, 
although some studies have shown that breast cancer is the most common among 
extrathymic malignancies [8]. Evidence suggests that the mechanism of neuronal attack 
in cancer is immune-mediated, which might explain how a second neurological relapse 
occurred following surgery of breast. According to the literature, the accuracy of the 
immunoprecipitation assay for the detection of almost all onconeural antibodies may 
be superior in the former assay [9]. In our particular case study, ONAs were tested with 
immunoﬂuorescence using patient serum samples and cannot be detected. Further 
studies are most likely needed to develop more sensitive assays, as the failure to detect 
onconeural antibodies in a patient with suspected PNS has important consequences for 
the treatment of the patient. 
Conclusion 
This case study highlights the importance of maintaining a high level of vigilance for 
the detection of PNS, even when ONAs are not detected, as the rapid identification and 
treatment of the underlying tumor offers the best chance for both a full recovery and 
the prevention of any further neurologic impairment. 
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Fig. 1. FDG-PET/CT detected increased metabolism in the right breast. 
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Fig. 2. Right thoracic interpectoral adenopathy detected by FDG-PET/CT. 
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Fig. 3. Suspicious retroareolar nodule of the right breast detected by breast MRI. 
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